Intellia Therapeutics (NTLA) Stock
Clinical stage biotech developing gene editing therapies for diseases. Here's the price, business snapshot, and what's worth knowing about Intellia Therapeutics in June 2026.
Intellia Therapeutics (NTLA) is a clinical-stage biotechnology company developing CRISPR/Cas9-based gene‑editing therapies. It is pursuing both in vivo and ex vivo approaches targeting genetic and liver diseases, with a pipeline of early clinical and preclinical programmes. Investors should understand that Intellia’s potential rests on demonstrating safe, durable benefits in human trials — a process that can take years and is subject to clinical, regulatory and competitive risk. With a market capitalisation near $2.9bn, the company’s valuation is sensitive to trial readouts, partnership deals and financing activity. Research and development spending is substantial and outcomes are uncertain, so share price volatility is common. This summary is educational only and not personalised financial advice; investors should consider their time horizon, risk tolerance and diversification needs before considering exposure to NTLA.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Intellia Therapeutics' stock with a target price of $52.33, indicating significant potential growth.
Financial Health
Intellia Therapeutics is generating modest revenue and cash flow, indicating stable but limited financial strength.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring NTLA
LNP Patent Holders Shape Drug Delivery Value 2025
The massive settlement between Moderna and Arbutus/Genevant highlights the critical value of the lipid nanoparticle (LNP) technology used in mRNA vaccines. This creates a potential investment opportunity in companies that hold key patents for drug delivery systems, as they may be poised for lucrative licensing deals or acquisitions.
Published: 4 March 2026
Explore BasketInvestment Opportunities in RNA Therapeutics Explained
Eli Lilly's $2.4 billion acquisition of Orna Therapeutics signals a major bet on circular RNA and in vivo cell engineering. This theme focuses on the broader ecosystem of companies developing the next-generation platforms and delivery technologies essential for advancing genetic medicine.
Published: 10 February 2026
Explore BasketBeyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: 5 August 2025
Explore BasketGene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: 30 July 2025
Explore BasketPioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: 21 July 2025
Explore BasketBiotech's IP Moat
This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.
Published: 11 July 2025
Explore BasketSynthetic-Bio Foundries
Discover companies that are programming living cells to create the materials of tomorrow. These carefully selected stocks represent pioneers in replacing petrochemical processes with cleaner, more efficient biological alternatives - essentially turning microbes into tiny manufacturing plants.
Published: 17 June 2025
Explore BasketPatient Platforms
This carefully curated collection features companies building the technological foundations that will power innovation for decades to come. Our analysts have identified businesses creating essential infrastructure in genomics, AI, robotics, and advanced computing—platforms that could define their industries and generate substantial long-term returns.
Published: 17 June 2025
Explore BasketDeep Future
This collection features companies pioneering revolutionary technologies that could transform our world in the decades ahead. Carefully selected by our analysts, these stocks represent visionary enterprises working on quantum computing, next-generation energy, and genetic medicine breakthroughs.
Published: 17 June 2025
Explore BasketSolar Eclipse Black Box
This carefully selected group of stocks represents breakthrough technologies developing in the shadows before their dramatic market emergence. Our professional analysts have identified companies pioneering quantum computing, gene editing, and other innovations with potential for explosive growth once they step into the spotlight.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
CRISPR Therapy Pipeline
Early clinical readouts could materially affect valuation, though trials can fail and timelines often slip.
Clinical Catalysts Ahead
Trial milestones, regulatory updates and partnerships tend to move the stock; outcomes remain binary and uncertain.
Long‑term Potential
Successful programmes could change care for some diseases, but benefits are speculative and carry substantial scientific and commercial risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
